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Aim
Antisense molecules targeting HIV-1 RNA have the
potential to be used as part of combination gene or drug
therapy to treat HIV-1 infection to reach a functional or
complete cure. Only a small number of extremely active
molecules currently exist and a treatment option has not
yet been identified in clinical trials. We have previously
developed new hepatitis delta virus (HDV)-derived ribo-
zymes (Rzs) called “switch on-off adaptor” (SOFA) to tar-
get HIV-1 RNA [1]. Our aim is to develop highly active
RNA-based molecules with complementary mechanisms,
which are able to reach a large number of HIV-1 variants.
Methods
We screened HIV-1 RNA to identify conserved target sites
for new HDV-Rzs [2]. We designed new SOFA-HDV-Rzs
against the Gag RNA and developed a rapid test to evalu-
ate the inhibition of HIV-1 production. We designed small
interfering (si) RNAs targeting the same region and tested
their activity on HIV-1 replication.
Results
We identified 13 conserved regions in the gag RNA and
constructed the corresponding Rzs. We transfected
HEK293T cells with these Rzs and HIV-1 molecular
clones. We identified one Rz that was particularly effica-
cious. We then constructed siRNAs and short hairpin (sh)
RNAs targeting the same sequence. The shRNA was very
active against HIV-1 clades B, C and A/G. Neither the Rz,
nor the shRNA disturbs the cellular transcriptome, sug-
gesting no toxicity. In lymphocytic cell lines, both the Rz
and the shRNA inhibit long-term HIV-1 replication [2].
Conclusions
We identified new SOFA-HDV-Rz, siRNA and shRNA
targeting HIV-1 Gag RNA. The shRNA is as active as the
only shRNA that has advanced to clinical trials and targets
more strains. Long-term inhibitory activity of these mole-
cules shows that this site is particularly accessible to other
antisense molecules. These molecules have a high poten-
tial to be used in combination gene therapy or as drugs
with appropriate delivery methods.
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